Sierocki Wojciech, Kornowska Ligia, Dudek Alicja, Szpakowicz Małgorzata, Dompe Claudia, Roszak Magdalena
Department of Continuing Education, University of Oxford, Oxford, United Kingdom.
Department of Pathophysiology, Poznan University of Medical Sciences, Poznan, Poland.
Front Oncol. 2025 Jun 26;15:1599741. doi: 10.3389/fonc.2025.1599741. eCollection 2025.
Breast cancer poses a significant public health challenge in Poland, with incidence rates exceeding the EU average and a concerning disparity between incidence and mortality. This review analyzes the key steps of breast cancer diagnosis and treatment in Poland, examining factors influencing therapeutic outcomes. We explore the complex interplay of epidemiological trends, prevention strategies, the impact of the National Oncology Strategy (NSO) and the National Cancer Network (KSO), access to care challenges, treatment protocols, and drug programs. While Poland has made strides in implementing comprehensive care pathways, including the DiLO card system and dedicated drug programs, significant gaps remain. Low screening participation, delays in diagnosis, limited access to innovative therapies, and reimbursement restrictions hinder optimal patient outcomes. This review highlights the urgent need for targeted interventions to address these challenges, improve early detection, enhance access to care, and ultimately reduce the burden of breast cancer for Polish patients.
乳腺癌在波兰构成了重大的公共卫生挑战,其发病率超过欧盟平均水平,且发病率与死亡率之间存在令人担忧的差距。本综述分析了波兰乳腺癌诊断和治疗的关键步骤,研究影响治疗结果的因素。我们探讨了流行病学趋势、预防策略、国家肿瘤战略(NSO)和国家癌症网络(KSO)的影响、获得护理的挑战、治疗方案以及药物计划之间的复杂相互作用。虽然波兰在实施综合护理途径方面取得了进展,包括DiLO卡系统和专门的药物计划,但仍存在重大差距。筛查参与率低、诊断延迟、获得创新疗法的机会有限以及报销限制阻碍了患者获得最佳治疗结果。本综述强调迫切需要采取有针对性的干预措施来应对这些挑战,改善早期检测,增加获得护理的机会,并最终减轻波兰患者的乳腺癌负担。